Ilacirnon sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 576602

CAS#: 1100319-36-5

Description: Ilacirnon sodium is a potent CCR2 antagonist that may be useful in the treatment of renal diseases including Focal Segmental Glomerulosclerosis and Diabetic Nephropathy.


Chemical Structure

img
Ilacirnon sodium
CAS# 1100319-36-5

Theoretical Analysis

MedKoo Cat#: 576602
Name: Ilacirnon sodium
CAS#: 1100319-36-5
Chemical Formula: C20H12ClF3N5NaO3S
Exact Mass: 517.02
Molecular Weight: 517.840
Elemental Analysis: C, 46.39; H, 2.34; Cl, 6.85; F, 11.01; N, 13.52; Na, 4.44; O, 9.27; S, 6.19

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: CCX-140 sodium; CCX 140 sodium; CCX140 sodium; Ilacirnon sodium

IUPAC/Chemical Name: 4-Chloro-N-(5-methyl-2-(7H-pyrrolo(2,3-d)pyrimidin-4-ylcarbonyl)-3-pyridinyl)-3-(trifluoromethyl)benzenesulfonamide, sodium salt

InChi Key: GJTHOZVZZCTXOH-UHFFFAOYSA-M

InChi Code: InChI=1S/C20H13ClF3N5O3S.Na/c1-10-6-15(29-33(31,32)11-2-3-14(21)13(7-11)20(22,23)24)17(26-8-10)18(30)16-12-4-5-25-19(12)28-9-27-16;/h2-9H,1H3,(H2,25,27,28,29,30);/q;+1/p-1

SMILES Code: [Na+].Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c([N-]S(=O)(=O)c4ccc(Cl)c(c4)C(F)(F)F)c1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 517.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Zheng B, Martín-Cleary C, Ruiz-Ortega M, Ortiz A, Fernandez-Fernandez B. Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opin Investig Drugs. 2016 Sep;25(9):1045-58. doi: 10.1080/13543784.2016.1196184. Epub 2016 Jun 13. Review. PubMed PMID: 27268955.

2: de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, Schall TJ; CCX140-B Diabetic Nephropathy Study Group. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96. doi: 10.1016/S2213-8587(15)00261-2. Epub 2015 Aug 9. PubMed PMID: 26268910.

3: Sullivan T, Miao Z, Dairaghi DJ, Krasinski A, Wang Y, Zhao BN, Baumgart T, Ertl LS, Pennell A, Seitz L, Powers J, Zhao R, Ungashe S, Wei Z, Boring L, Tsou CL, Charo I, Berahovich RD, Schall TJ, Jaen JC. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am J Physiol Renal Physiol. 2013 Nov 1;305(9):F1288-97. doi: 10.1152/ajprenal.00316.2013. Epub 2013 Aug 28. PubMed PMID: 23986513; PubMed Central PMCID: PMC4073927.

4: Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, Krasinski A, Walters MJ, Powers JP, Dairaghi DJ, Baumgart T, Seitz LC, Berahovich RD, Schall TJ, Jaen JC. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism. 2013 Nov;62(11):1623-32. doi: 10.1016/j.metabol.2013.06.008. Epub 2013 Aug 15. PubMed PMID: 23953944.

5: Sullivan TJ, Dairaghi DJ, Krasinski A, Miao Z, Wang Y, Zhao BN, Baumgart T, Berahovich R, Ertl LS, Pennell A, Seitz L, Miao S, Ungashe S, Wei Z, Johnson D, Boring L, Tsou CL, Charo IF, Bekker P, Schall TJ, Jaen JC. Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications. J Pharmacol Exp Ther. 2012 Jun 5. doi: 10.1124/jpet.111.190918. Epub 2012 Jun 5. Retraction in: J Pharmacol Exp Ther. 2012 Jul;342(1):234. PubMed PMID: 22378937.